Compare AbbVie Inc (ABBV) vs Davita Inc (DVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Davita Inc — how do they compare? AbbVie Inc trades at $253.74 (market cap $449.91B), while Davita Inc trades at $231.72 (market cap $15.04B). The key difference: AbbVie Inc is far larger — about 29.9× Davita Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| ABBV | DVA | |
|---|---|---|
Market Cap | $449.91B | $15.04B |
Sector | Health | Health |
52-Week High | $261.07 | $235.71 |
52-Week Low | $184.85 | $103.87 |
Enterprise Value | $513.38B | $27.59B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
DaVita (DVA) trades at $234.31, showing modest daily decline but maintaining strong momentum near 52-week highs. The stock exhibits bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, revenue growth continues with $13.64B in 2025, while net margins of 5.65% reflect steady profitability. Recent news highlights DVA's expansion in kidney care delivery and AI-driven scheduling improvements, positioning the company for continued growth in specialized healthcare services.
Investment outlook remains positive with analyst consensus favoring Buy ratings (39%) and price targets averaging $211. Key opportunities include expanding kidney care services and operational efficiencies, while risks involve high debt levels (65.55% debt-to-asset ratio) and healthcare regulatory pressures. Current valuation metrics (P/E 22.71, P/S 1.24) appear reasonable given growth prospects, though the stock trades above consensus targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
